These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
659 related articles for article (PubMed ID: 33691383)
1. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. Fiorcari S; Atene CG; Maffei R; Debbia G; Potenza L; Luppi M; Marasca R Haematologica; 2021 Aug; 106(8):2265-2268. PubMed ID: 33691383 [No Abstract] [Full Text] [Related]
2. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia. İskender G; İskender D; Ertek M Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674 [No Abstract] [Full Text] [Related]
3. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis. Molica S; Baumann T; Giannarelli D Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324 [No Abstract] [Full Text] [Related]
4. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib. Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076 [No Abstract] [Full Text] [Related]
5. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312 [No Abstract] [Full Text] [Related]
7. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562 [No Abstract] [Full Text] [Related]
8. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. Molica S; Giannarelli D; Baumann T; Montserrat E Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067 [No Abstract] [Full Text] [Related]
9. Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia. Molica S; Allsup DJ; Polliack A Leuk Lymphoma; 2022 Aug; 63(8):1771-1773. PubMed ID: 35703117 [No Abstract] [Full Text] [Related]
10. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100 [TBL] [Abstract][Full Text] [Related]
11. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543 [No Abstract] [Full Text] [Related]
12. Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia. Khan S; Durairaj S; Phumphukhieo P; Holding S; Allsup D Leuk Lymphoma; 2021 Jul; 62(7):1786-1789. PubMed ID: 33596758 [No Abstract] [Full Text] [Related]